[CAS NO. 58-14-0] Pyrimethamine
PRODUCTS SPECIFICATIONS [58-14-0]
DESCRIPTION [58-14-0]
Overview
| MDL | MFCD00057350 |
|---|---|
| Molecular Weight | 248.71 |
| Molecular Formula | C12H13ClN4 |
| SMILES | NC1=NC(N)=C(C2=CC=C(Cl)C=C2)C(CC)=N1 |
5 Publications Citing Use of MCE
Summary
Pyrimethamine (Pirimecidan) is a potent, orally active dihydrofolate reductase (DHFR) inhibitor. Pyrimethamine is an antimalarial agent. Pyrimethamine affects the nucleoprotein metabolism of malarial parasites by interference in the folic–folinic acid systems and affects cell division by inhibiting the conversion of dihydrofolate to tetrahydrofolate [1] [2] .
In Vitro
Pyrimethamine (Pirimecidan; 4 nM-4 μM; 24 h; LLC-MK2 cells with T. gondii ) combination of Fluconazole (FLZ) (HY-B0101) inhibits T. gondii activity with IC 50 values of 0.23, 0.19, 0.23, 0.34, 0.14, and 0.19 μM for FLZ concentration at 0, 0.05, 0.1, 0.5, 1.0, and 3.0 μM, respectively [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | LLC-MK2 cells with T. gondii |
| Concentration: | 4 nM-4 μM |
| Incubation Time: | 24 hours |
| Result: | Inhibited T. gondii activity and decreased parasite proliferation index. |
In Vivo
Pyrimethamine (Pirimecidan; 1 mg/kg; i.g.; daily, for 10 d; female CF1 mice with T. gondii xenograft) combination of Fluconazole (FLZ) (HY-B0101) and Sulfadiazine (HY-B0273) increases protection from death [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Female CF1 mice (18-22 g; 4-6 week of age) with T. gondii xenograft [1] |
| Dosage: | Oral gavage; daily, for 10 days |
| Administration: | 1 mg/kg; 10 mg/kg ( Fluconazole (HY-B0101)), 40 mg/kg ( Sulfadiazine (HY-B0273)) |
| Result: | Increased mouse survival compared to treatment with SDZ/PYR alone. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03944317 | Federal Medical Centre, Owo |
Malaria in Pregnancy|Pregnancy
|
June 1, 2019 | Not Applicable |
| NCT00399074 | Makerere University |
Sickle Cell Anemia|Malaria
|
October 2006 | Phase 3 |
| NCT00000666 | National Institute of Allergy and Infectious Diseases (NIAID) |
Toxoplasmosis, Cerebral|HIV Infections
|
Not Applicable | |
| NCT00004317 | National Institute of Allergy and Infectious Diseases (NIAID)|University of Chicago|Office of Rare Diseases (ORD) |
Toxoplasmosis
|
July 2000 | Phase 4 |
| NCT05354258 | London School of Hygiene and Tropical Medicine|Université de Thies, UFR Santé, Senegal |
Malaria|Soil Transmitted Helminths|Schistosomiasis|Integrated Control|Seasonal Malaria Chemoprevention|Mass Drug Administration With Anthelminthic Drugs
|
June 16, 2022 | Not Applicable |
| NCT00000973 | National Institute of Allergy and Infectious Diseases (NIAID)|Glaxo Wellcome |
Toxoplasmosis, Cerebral|HIV Infections
|
Phase 1 | |
| NCT03525730 | Erasmus Medical Center |
HIV-1-infection
|
April 18, 2018 | Phase 1|Phase 2 |
| NCT00679744 | Exsar Corporation|University Hospitals Cleveland Medical Center|NYU Langone Health|The Hospital for Sick Children |
G(M2) Ganglioside|Tay-Sachs Disease Ganglioside|Sandhoff Disease Ganglioside
|
May 2008 | Phase 1 |
| NCT01066663 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Beth Israel Deaconess Medical Center|Lymphoma Research Foundation |
Chronic Lymphocytic Leukemia|Small Lymphocytic Leukemia
|
March 2010 | Phase 1|Phase 2 |
| NCT03952650 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
Malaria
|
May 23, 2019 | Phase 1|Phase 2 |
| NCT00300404 | Zentrum für Integrative Psychiatrie|Stanley Medical Research Institute |
Schizophrenia|Major Depression
|
January 2002 | Phase 3 |
| NCT05323721 | Malaria Consortium |
Malaria
|
June 1, 2022 | Phase 4 |
| NCT03454048 | Radboud University Medical Center|The PATH Malaria Vaccine Initiative (MVI)|QIMR Berghofer Medical Research Institute |
Malaria,Falciparum|Gametocytes|Controlled Human Malaria Infection|Transmission
|
May 7, 2018 | Not Applicable |
| NCT00304980 | Institute of Tropical Medicine, Belgium |
Plasmodium Falciparum Malaria
|
March 2003 | Not Applicable |
| NCT04149106 | University Clinical Research Center, Mali|Tulane University|University of South Florida|University of Copenhagen|Deakin University|Johns Hopkins University |
Malaria,Falciparum
|
July 1, 2019 | Phase 1 |
| NCT00000674 | National Institute of Allergy and Infectious Diseases (NIAID)|Upjohn|Glaxo Wellcome |
Toxoplasmosis, Cerebral|HIV Infections
|
Not Applicable | |
| NCT05471544 | Malaria Consortium |
Malaria
|
July 18, 2022 | Phase 3 |
| NCT00065390 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
Autoimmune Disease|Lymphatic Disease|Lymphoproliferative Disorder
|
July 2003 | Phase 1 |
| NCT04086719 | Bristol-Myers Squibb |
Healthy Male Volunteers
|
September 12, 2019 | Phase 1 |
| NCT00002064 | Palo Alto Medical Foundation|NIH AIDS Clinical Trials Information Service |
Toxoplasmosis, Cerebral|HIV Infections
|
Not Applicable | |
| NCT00000794 | National Institute of Allergy and Infectious Diseases (NIAID) |
Toxoplasmosis, Cerebral|HIV Infections
|
Phase 2 | |
| NCT00000643 | National Institute of Allergy and Infectious Diseases (NIAID) |
Toxoplasmosis, Cerebral|HIV Infections
|
Phase 2 | |
| NCT01973933 | Seoul National University Hospital |
Healthy
|
June 2013 | Phase 1 |
| NCT00646126 | Tropical Medicine Research Institute|London School of Hygiene and Tropical Medicine|International Atomic Energy Agency |
Plasmodium Falciparum|Asymptomatic Parataemia|Sub Patent Parasitaemia
|
August 2005 | Phase 3 |
| NCT00367081 | Rajavithi Hospital|Chiang Mai University |
Toxoplasmic Encephalitis|AIDS
|
May 2003 | Phase 4 |
| NCT00000966 | Pfizer|National Institute of Allergy and Infectious Diseases (NIAID) |
Toxoplasmosis, Cerebral|HIV Infections
|
Phase 1 | |
| NCT03258762 | GlaxoSmithKline |
Toxoplasmosis
|
September 25, 2017 | Phase 1 |
| NCT00000727 | National Institute of Allergy and Infectious Diseases (NIAID) |
Pneumonia, Pneumocystis Carinii|HIV Infections
|
Phase 3 | |
| NCT00766662 | University of Bamako|UNICEF |
Malaria
|
October 2006 | Not Applicable |
| NCT02511054 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
Malaria
|
July 21, 2015 | Phase 1 |
| NCT01102686 | The Hospital for Sick Children |
Gangliosidoses, GM2|Sandhoff Disease|Tay-Sachs Disease
|
August 2009 | Phase 1|Phase 2 |
| NCT03083847 | National Institute of Allergy and Infectious Diseases (NIAID)|Sanaria Inc.|National Institutes of Health Clinical Center (CC) |
Malaria
|
June 5, 2017 | Phase 1 |
| NCT05426434 | Menzies School of Health Research|Papua New Guinea Institute of Medical Research|University of Melbourne|Curtin University|Liverpool School of Tropical Medicine |
Malaria|Malaria in Pregnancy|Pregnancy Related
|
August 31, 2022 | Phase 3 |
| NCT04783051 | University of Kinshasa|European and Developing Countries Clinical Trials Partnership (EDCTP)|Novartis |
Malaria in Pregnancy
|
May 6, 2021 | Phase 3 |
| NCT00453856 | Albert Schweitzer Hospital|Bill and Melinda Gates Foundation |
Malaria
|
March 2007 | Phase 4 |
| NCT03057990 | Montefiore Medical Center|Albert Einstein College of Medicine |
Myelodysplastic Syndromes
|
September 11, 2019 | Phase 1 |
| NCT05478954 | Malaria Consortium |
Malaria
|
July 15, 2022 | Phase 4 |
| NCT00529620 | London School of Hygiene and Tropical Medicine|Cheikh Anta Diop University, Senegal |
Malaria
|
September 2007 | Phase 3 |
| NCT01083667 | Weill Medical College of Cornell University|Muscular Dystrophy Association |
Familial Amyotrophic Lateral Sclerosis
|
November 2009 | Phase 1|Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 20 mg/mL ( 80.41 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.0207 mL | 20.1037 mL | 40.2075 mL |
| 5 mM | 0.8041 mL | 4.0207 mL | 8.0415 mL |
| 10 mM | 0.4021 mL | 2.0104 mL | 4.0207 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (10.05 mM); Clear solution
References
- [1] Aikawa M, et, al. Studies on nuclear division of a malarial parasite under pyrimethamine treatment. J Cell Biol. 1968 Dec;39(3):749-54.
- [2] Martins-Duarte ÉS, et, al. Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model. Exp Parasitol. 2013 Mar;133(3):294-9.
Synonyms